TY - JOUR
T1 - A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase
AU - Quintás-Cardama, Alfonso
AU - Kantarjian, Hagop
AU - Garcia-Manero, Guillermo
AU - O'Brien, Susan
AU - Faderl, Stefan
AU - Ravandi, Farhad
AU - Giles, Francis
AU - Thomas, Deborah
AU - Wierda, William
AU - Cortes, Jorge
PY - 2007/2/1
Y1 - 2007/2/1
N2 - Imatinib is the single most effective agent in chronic myelogenous leukemia (CML) in blast phase (BP), inducing hematologic responses in 30-50% of patients. However, only a few of these are complete (CHR) and durable. Imatinib is synergistic with idarubicin and cytarabine. We administered imatinib 600 mg/day, cytarabine 10 mg/day subcutaneous, and idarubicin 12 mg/m2 intravenous every 14 days in 19 patients with CML in myeloid BP. Fourteen patients (74%) achieved a hematologic response: CHR in 9 (47%) (3 with complete and 1 with minor cytogenetic responses) and return to chronic phase (RTC) in 5 (26%). Median duration of response was 10 weeks (range, 2-89). Six patients received allogeneic stem cell transplantation: 4 CHR, 1 chronic phase and 1 BP. Median survival was 5 months (range, 2-20 months). This outpatient regimen is effective and well tolerated and perhaps superior to single-agent imatinib for patients in myeloid BP.
AB - Imatinib is the single most effective agent in chronic myelogenous leukemia (CML) in blast phase (BP), inducing hematologic responses in 30-50% of patients. However, only a few of these are complete (CHR) and durable. Imatinib is synergistic with idarubicin and cytarabine. We administered imatinib 600 mg/day, cytarabine 10 mg/day subcutaneous, and idarubicin 12 mg/m2 intravenous every 14 days in 19 patients with CML in myeloid BP. Fourteen patients (74%) achieved a hematologic response: CHR in 9 (47%) (3 with complete and 1 with minor cytogenetic responses) and return to chronic phase (RTC) in 5 (26%). Median duration of response was 10 weeks (range, 2-89). Six patients received allogeneic stem cell transplantation: 4 CHR, 1 chronic phase and 1 BP. Median survival was 5 months (range, 2-20 months). This outpatient regimen is effective and well tolerated and perhaps superior to single-agent imatinib for patients in myeloid BP.
UR - http://www.scopus.com/inward/record.url?scp=34247853362&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34247853362&partnerID=8YFLogxK
U2 - 10.1080/10428190601075973
DO - 10.1080/10428190601075973
M3 - Review article
C2 - 17325887
AN - SCOPUS:34247853362
SN - 1042-8194
VL - 48
SP - 283
EP - 289
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 2
ER -
